Testing inotuzumab for children with early ALL relapse
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 1 to under 18 years
- Your ALL must be a first relapse of the “HR” or “VHR” type, as defined by the study, and your tumor cells must be CD22-positive
- Bone marrow must have at least 5% leukemia cells
- Your liver, kidney, and bilirubin blood tests must be within allowed limits before starting
- Your heart function must be strong enough (shortening fraction at least 30% or ejection fraction over 50%)
- You cannot have certain prior treatments or conditions (like prior transplant for ALL or CAR T therapy), and infections must be controlled
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a treatment strategy for newly diagnosed Ph+ B-cell acute lymphoblastic leukemia (ALL) that avoids traditional chemotherapy during the early “induction” phase, using inotuzumab ozogamicin instead. If it works, it could help control the leukemia while reducing exposure to chemotherapy early on.
This trial tests new combinations of targeted drugs (inotuzumab ozogamicin and blinatumomab) for children whose B-cell acute lymphoblastic leukemia (ALL) has come back for the first time. It aims to find the best treatment based on how well the leukemia responds.
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
This trial studies inotuzumab ozogamicin, a leukemia-targeting medicine, given after an allogeneic stem cell transplant. It’s for people with CD22-positive acute lymphoblastic leukemia (ALL) to help prevent relapse and improve outcomes after transplant.
This trial studies inotuzumab, a targeted cancer drug, for people whose B-cell ALL has returned at a very low level after a bone-marrow or stem-cell transplant. If you qualify, it may help push the leukemia back under control after transplant.
This trial tests whether a low dose of a targeted drug called inotuzumab ozogamicin, given after a stem cell transplant, can help prevent acute lymphoblastic leukemia from coming back. It is for people who have already had a transplant and are at high risk for relapse.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.